相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak et al.
CLINICAL CANCER RESEARCH (2021)
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Benjamin M. Ellingson et al.
CLINICAL CANCER RESEARCH (2021)
Variability and Standardization of Quantitative Imaging Monoparametric to Multiparametric Quantification, Radiomics, and Artificial Intelligence
Akifumi Hagiwara et al.
INVESTIGATIVE RADIOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors
Joseph Song et al.
NEURO-ONCOLOGY (2020)
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden
Kunal S. Patel et al.
NEUROSURGERY (2020)
Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma
Kunal S. Patel et al.
SCIENTIFIC REPORTS (2020)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Normalization of ADC does not improve correlation with overall survival in patients with high-grade glioma (HGG)
Lei Qin et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2018)
Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection
Stefanie Bette et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape
Benjamin M. Ellingson et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials
Benjamin M. Ellingson et al.
CLINICAL CANCER RESEARCH (2017)
Mechanical forces in the immune system
Morgan Huse
NATURE REVIEWS IMMUNOLOGY (2017)
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma
Benjamin M. Ellingson et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma
Andrew Elson et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
Pivotal role for decorin in angiogenesis
Hannu Jarvelainen et al.
MATRIX BIOLOGY (2015)
Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immunerelated Adverse Events
Jennifer J. Kwak et al.
RADIOGRAPHICS (2015)
Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?
Amanda J. Walker et al.
FUTURE ONCOLOGY (2014)
Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial
Benjamin M. Ellingson et al.
RADIOLOGY (2014)
Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2013)
Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics
Daniel Rodriguez Gutierrez et al.
NEURO-ONCOLOGY (2013)
The Correlation between Apparent Diffusion Coefficient and Tumor Cellularity in Patients: A Meta-Analysis
Lihua Chen et al.
PLOS ONE (2013)
Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls
S. Mong et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2012)
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study
Whitney B. Pope et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2012)
Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab
Benjamin M. Ellingson et al.
NEURO-ONCOLOGY (2011)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Validation of Functional Diffusion Maps (fDMs) as a Biomarker for Human Glioma Cellularity
Benjamin M. Ellingson et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2010)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The matricellular functions of small leucine-rich proteoglycans (SLRPs)
Rosetta Merline et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2009)
Variability in Absolute Apparent Diffusion Coefficient Values across Different Platforms May Be Substantial: A Multivendor, Multi-institutional Comparison Study
Makoto Sasaki et al.
RADIOLOGY (2008)
User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability
Paul A. Yushkevich et al.
NEUROIMAGE (2006)
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors
TL Chenevert et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma
RK Gupta et al.
JOURNAL OF NEURO-ONCOLOGY (2000)
分享论文
